From BigGo Finance · BigGo Finance · · 1m 30s
Jindike's flu vaccine approval risks delisting
China's Jindike gets flu shot approval but may miss revenue target, risking stock delisting.
In brief
China's Jindike gets flu shot approval but may miss revenue target, risking stock delisting. China's Jindike faces delisting risk after full-year revenue may fall below 100 million yuan due to limited sales window and three years of losses. Originally reported by BigGo Finance.
Jindike wins flu vaccine approval
China's Jindike received marketing approval for its trivalent influenza vaccine after WHO revised recommended strains.
“China's Jindike has received marketing approval for its trivalent influenza vaccine, filling a product gap left by the withdrawal of quadrivalent vaccines after the World Health Organization revised its recommended strain composition.”
Limited sales window for flu vaccine
The trivalent vaccine requires batch release approval and government procurement bidding, leaving minimal sales time this flu season.
“Jindike acknowledged that the trivalent vaccine has only just been approved, and the product must obtain a biological product batch release certificate before it can be marketed.”
Full-year revenue may fall below 100 million yuan
Jindike expects full-year revenue to fall below 100 million yuan (approximately $15.0 million) with no profit prospects.
“Jindike expects full-year revenue may fall below 100 million yuan (approximately $15.0 million) with no prospect of turning a profit”
Three years of consecutive losses
Jindike has posted losses for three consecutive years since 2023 with first-half 2026 revenue of 910,900 yuan.
“The company has posted losses for three consecutive years since 2023, with first-half 2026 revenue of just 910,900 yuan (approximately $140,000)”
Intense market competition
More than 20 similar trivalent flu vaccines are approved in China, intensifying competition for Jindike.
“Jindike disclosed that more than 20 trivalent influenza vaccine products have been formally approved for marketing in China”
Delisting risk warning looming
Jindike faces delisting risk if full-year revenue falls below 100 million yuan and net profit remains negative.
“if full-year revenue falls below 100 million yuan (approximately $15.0 million) and net profit is negative, the Shanghai Stock Exchange will impose a delisting risk warning”
Jindike's financial outlook
Jindike's net loss attributable to shareholders was 51.0704 million yuan with revenue down 74.15% year-on-year.
“Net loss attributable to shareholders was 51.0704 million yuan (approximately $7.6 million), with the loss widening further compared to the same period last year”
Jindike's response to challenges
Jindike is advancing post-approval work to complete product filling, packaging, and batch release quickly.
“The company is urgently advancing post-approval work to complete product filling, packaging, and batch release as quickly as possible”
Delisting risk remains high
Jindike's revenue is unlikely to exceed 100 million yuan before year-end due to limited sales window.
“Given that first-half 2026 revenue was less than 1 million yuan, even if the trivalent vaccine ramps up quickly in the fourth quarter, the difficulty of pushing full-year revenue above the 100 million yuan threshold in the remaining time is self-evident”
In short
China's Jindike faces delisting risk after full-year revenue may fall below 100 million yuan due to limited sales window and three years of losses.
